中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
10期
795-799
,共5页
李兆沛%韩俊庆%孟祥文%杨玉峰
李兆沛%韓俊慶%孟祥文%楊玉峰
리조패%한준경%맹상문%양옥봉
结直肠肿瘤%预后%血管内皮生长因子%白细胞介素6%C反应蛋白
結直腸腫瘤%預後%血管內皮生長因子%白細胞介素6%C反應蛋白
결직장종류%예후%혈관내피생장인자%백세포개소6%C반응단백
Colorectal neoplasms%Prognosis%Vascular endothelial growth factor%Interleukin-6%C-reactive protein
目的 探讨结直肠癌患者术前血清血管内皮生长因子(VEGF)、白细胞介素6(IL-6)和C反应蛋白(CRP)水平与临床病理的关系及其对预后的临床意义.方法 采用酶联免疫吸附法检测79例结直肠癌患者血清VEGF和IL-6,采用免疫比浊法检测血清CRP,比较结直肠癌患者与健康对照者的血清VEGF、IL-6和CRP水平.采用Kaplan-Meier法分析结直肠癌患者5年生存率,采用Log rank 单因素分析预后不良因素.结果 结直肠癌组血清VEGF、IL-6和CRp分别为(591±312)pg/ml、(13.2±3.7)pg/ml和(1.14±0.87)mg/dl,健康对照组分别为(321±210)pg/ml、(5.4±2.0)pg/ml和(0.39±0.35)mg/dl,其中VEGF和CRP间差异有统计学意义(P＜0.001,P=0.002).男性患者和女性患者的VEGF水平分别为(638±387)pg/ml和(552±271)pg/ml,差异有统计学意义(P=0.042);肿瘤＜5 cm和肿瘤≥5 cm患者的VEGF表达分别为(538±275)pg/ml和(647±331)pg/ml,差异有统计学意义(P=0.009).男性患者和女性患者的IL-6表达分别为(11.7±3.2)pg/ml和(15.2±4.0)pg/ml,差异有统计学意义(P=0.011).VEGF＜591 pg/ml和≥591 pg/ml患者的5年生存率分别为86.8%(33/38)和73.2%(30/41),IL-6＜13.2 pg/ml和≥13.2 pg/ml患者的5年生存率分别为82.9%(34/41)和76.3%(29/38),CRP＜1.14 mg/dl和≥1.14 mg/dl的5年生存率分别为81.4%(35/43)和77.8%(28/36).Log rank单因素分析显示,VEGF水平是影响结直肠癌预后的相关因素(P＜0.05).Logistic回归分析显示,肿瘤大小和VEGF水平为结直肠癌患者预后的危险因素(P=0.032,OR=0.985;P=0.011,OR=0.976).结论 血清VEGF和IL-6表达具有性别差异,血清VEGF检测可作为结直肠癌患者的临床诊断标志之一,对患者的预后具有重要的临床意义.
目的 探討結直腸癌患者術前血清血管內皮生長因子(VEGF)、白細胞介素6(IL-6)和C反應蛋白(CRP)水平與臨床病理的關繫及其對預後的臨床意義.方法 採用酶聯免疫吸附法檢測79例結直腸癌患者血清VEGF和IL-6,採用免疫比濁法檢測血清CRP,比較結直腸癌患者與健康對照者的血清VEGF、IL-6和CRP水平.採用Kaplan-Meier法分析結直腸癌患者5年生存率,採用Log rank 單因素分析預後不良因素.結果 結直腸癌組血清VEGF、IL-6和CRp分彆為(591±312)pg/ml、(13.2±3.7)pg/ml和(1.14±0.87)mg/dl,健康對照組分彆為(321±210)pg/ml、(5.4±2.0)pg/ml和(0.39±0.35)mg/dl,其中VEGF和CRP間差異有統計學意義(P＜0.001,P=0.002).男性患者和女性患者的VEGF水平分彆為(638±387)pg/ml和(552±271)pg/ml,差異有統計學意義(P=0.042);腫瘤＜5 cm和腫瘤≥5 cm患者的VEGF錶達分彆為(538±275)pg/ml和(647±331)pg/ml,差異有統計學意義(P=0.009).男性患者和女性患者的IL-6錶達分彆為(11.7±3.2)pg/ml和(15.2±4.0)pg/ml,差異有統計學意義(P=0.011).VEGF＜591 pg/ml和≥591 pg/ml患者的5年生存率分彆為86.8%(33/38)和73.2%(30/41),IL-6＜13.2 pg/ml和≥13.2 pg/ml患者的5年生存率分彆為82.9%(34/41)和76.3%(29/38),CRP＜1.14 mg/dl和≥1.14 mg/dl的5年生存率分彆為81.4%(35/43)和77.8%(28/36).Log rank單因素分析顯示,VEGF水平是影響結直腸癌預後的相關因素(P＜0.05).Logistic迴歸分析顯示,腫瘤大小和VEGF水平為結直腸癌患者預後的危險因素(P=0.032,OR=0.985;P=0.011,OR=0.976).結論 血清VEGF和IL-6錶達具有性彆差異,血清VEGF檢測可作為結直腸癌患者的臨床診斷標誌之一,對患者的預後具有重要的臨床意義.
목적 탐토결직장암환자술전혈청혈관내피생장인자(VEGF)、백세포개소6(IL-6)화C반응단백(CRP)수평여림상병리적관계급기대예후적림상의의.방법 채용매련면역흡부법검측79례결직장암환자혈청VEGF화IL-6,채용면역비탁법검측혈청CRP,비교결직장암환자여건강대조자적혈청VEGF、IL-6화CRP수평.채용Kaplan-Meier법분석결직장암환자5년생존솔,채용Log rank 단인소분석예후불량인소.결과 결직장암조혈청VEGF、IL-6화CRp분별위(591±312)pg/ml、(13.2±3.7)pg/ml화(1.14±0.87)mg/dl,건강대조조분별위(321±210)pg/ml、(5.4±2.0)pg/ml화(0.39±0.35)mg/dl,기중VEGF화CRP간차이유통계학의의(P＜0.001,P=0.002).남성환자화녀성환자적VEGF수평분별위(638±387)pg/ml화(552±271)pg/ml,차이유통계학의의(P=0.042);종류＜5 cm화종류≥5 cm환자적VEGF표체분별위(538±275)pg/ml화(647±331)pg/ml,차이유통계학의의(P=0.009).남성환자화녀성환자적IL-6표체분별위(11.7±3.2)pg/ml화(15.2±4.0)pg/ml,차이유통계학의의(P=0.011).VEGF＜591 pg/ml화≥591 pg/ml환자적5년생존솔분별위86.8%(33/38)화73.2%(30/41),IL-6＜13.2 pg/ml화≥13.2 pg/ml환자적5년생존솔분별위82.9%(34/41)화76.3%(29/38),CRP＜1.14 mg/dl화≥1.14 mg/dl적5년생존솔분별위81.4%(35/43)화77.8%(28/36).Log rank단인소분석현시,VEGF수평시영향결직장암예후적상관인소(P＜0.05).Logistic회귀분석현시,종류대소화VEGF수평위결직장암환자예후적위험인소(P=0.032,OR=0.985;P=0.011,OR=0.976).결론 혈청VEGF화IL-6표체구유성별차이,혈청VEGF검측가작위결직장암환자적림상진단표지지일,대환자적예후구유중요적림상의의.
Objective To determine the preoperative serum VEGF, IL-6, and CRP levels in colorectal carcinoma, and to explore their correlation with disease status and prognosis. Methods Serum VEGF and IL-6 levels were assessed using ELISA, and CRP was measured by immunoturbidimetry. They were compared between the colorectal carcinoma group and the control group. The five-year survival rate and poor prognostic factors were analyzed by Kaplan-Meier and Log-rank method, respectively. Results The serum VEGF, IL-6, and CRP levels in colorectal carcinoma were (591 ±312) pg/ml, (13.2 ±3.7) pg/ml,and (1.14 ±0.87) mg/dl, respectively, higher than that in the control group. The two groups showed significant difference in VEGF and CRP ( P ＜ 0.001, P = 0.002). VEGF expression was higher in male than that in female [(638 ±387) pg/ml vs. (552 ±271) pg/ml, P =0.042]. The cases with tumor size smaller than 5 cm had lower VEGF expression compared with that in cases with tumor size ≥ 5 cm[(538 ±275) pg/ml vs. (647 ± 331 ) pg/ml, P = 0.009 ]. IL-6 expression showed significant difference in males ( 11.7 ±3.2) and females ( 15.2 ±4.0) pg/ml, ( P =0.011 ). The five-year survival rate in the group with VEGF ＜591 pg/ml was 86.8% (33/38), higher than that in the ≥591 pg/m group. High VEGF level tended to reduce survival (x2 =0. 933, P=0.344). VEGF≥591 pg/ml was a factor of poor prognosis in colorectal carcinoma, assessed by Log-rank methods ( P ＜ 0.05). Tumor size and VEGF concentration were risk factors of prognosis (P=0.032, 0R=0.985;P=0.011, OR=0.976). Conclusions Serum VEGF and IL-6 expressions have gender differences. Serum VEGF can be used as a biomaker of clinical diagnosis of colorectal cancer, and has an important significance on the prognosis of patients.
